Results 131 to 140 of about 10,082,212 (260)

Facts 1988-1989 North Carolina Central University [PDF]

, 1988
Facts 1988-1989 North Carolina Central ...
Office of Institutional Research and Analysis , North Carolina Central University, NC DOCKS at North Carolina Central University   +1 more
core  

First Record of Tasmanian Devils in the Pilbara: Late Quaternary Subfossils From Juukan Gorge, Puutu Kunti Kurrama Country, and Insights Into Human—Faunal Relationships and Extinction

Archaeology in Oceania, EarlyView.
ABSTRACT This study presents the first unequivocal evidence for the presence of Tasmanian devils (Sarcophilus harrisii) in the Pilbara region of northwestern Australia, based on material recovered from archaeological excavations at Juukan Gorge on Puutu Kunti Kurrama and Pinikura country.
Timothy J. Churchill, Michael Slack, Elise Matheson, Liam Neill, Wanchese M. Saktura, Gavin Ashburton   +5 more
wiley   +1 more source

Gender Equity in Rheumatology Research: Global Analysis of Authors

Arthritis &Rheumatology, EarlyView.
Objective To investigate gender representation of authors in rheumatology research over the last decade. Methods Using metadata from original and review articles published between 2015 and 2024 in SCImago top two quartile (Q1, Q2) rheumatology journals, author gender was classified using two public databases.
Michael Girdwood, Jean W. Liew, Ida K. Haugen, Marcella F. Pazzinatto, Andrea M. Bruder, Nicola Dalbeth, Adam G. Culvenor, Tuhina Neogi   +7 more
wiley   +1 more source

[Central Pacific, Locomotive 59, ''Pluto'']

This photograph shows a train which includes Central Pacific Railroad cars 2033, 1024, and 342.Verso: [handwritten in pencil] Central Pacific Railroad #59, ''Pluto'' manufactured by Schnectady Locomotive Works ...
Unknown
core  

Facts 1987-1988 North Carolina Central University [PDF]

, 1987
Facts 1987-1988 North Carolina Central ...
Office of Institutional Research and Analysis , North Carolina Central University, NC DOCKS at North Carolina Central University   +1 more
core  

Efficacy and Safety of Nanoencapsulated Sirolimus Plus Pegadricase: Results From the Randomized, Placebo‐Controlled Phase 3 Trials

Arthritis &Rheumatology, EarlyView.
Objective DISSOLVE I and II examined the efficacy and safety of nanoencapsulated sirolimus (NAS) plus pegadricase (NASP) in patients with uncontrolled gout (UG). Methods In these double‐blind, placebo‐controlled Phase 3 trials of NASP, patients were randomized 1:1:1 to infusions of high‐dose (HD) or low‐dose (LD) NAS plus pegadricase (HD NASP, LD NASP,
Herbert S. B. Baraf, Puja P. Khanna, Milan Petronijevic, Mamuka Lortkipanidze, Anand Patel, Kwabena Ayesu, Michael H. Pillinger, Atul Singhal, Joanna Sobierska, Jacquie Christie, Peter Traber, Rehan Azeem, Wesley DeHaan, Hugues Santin‐Janin, Bhavisha Desai, Alan Kivitz   +15 more
wiley   +1 more source

Facts 1996-1997 North Carolina Central University [PDF]

, 1996
Facts 1996-1997 North Carolina Central ...
Office of Institutional Research and Analysis , North Carolina Central University, NC DOCKS at North Carolina Central University   +1 more
core  

Pharmacokinetics, Effectiveness and Safety of Certolizumab Pegol in Children and Adolescents With Active Juvenile Idiopathic Arthritis: 9+‐Year Results From a Multicenter, Open‐Label Study

Arthritis &Rheumatology, EarlyView.
Objective The purpose of this study was to assess the pharmacokinetics, effectiveness, safety, and immunogenicity of certolizumab pegol (CZP) in polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods Pediatric Arthritis Study of Certolizumab Pegol (NCT01550003), a multicenter, open‐label study, enrolled patients aged 2 to 17 years with ...
Hermine I. Brunner, Lyudmila Grebenkina, Irina Nikishina, Ekaterina Alexeeva, Vyacheslav Chasnyk, Carlos Abud‐Mendoza, Nadina Rubio‐Pérez, Heinrike Schmeling, María del Rocio Maldonado‐Velázquez, Diane Brown, Andrew Zeft, Esi Morgan, C. Egla Rabinovich, Daniel Kingsbury, Hulya Bukulmez, Beth Gottlieb, Thomas Griffin, Lisa Imundo, Stacey Tarvin, Earl Silverman, Laura Shaughnessy, Saori Shimizu, Paulette Williams, Rocío Lledó‐García, Gauri Utturkar, Baran Ufuktepe, Alberto Martini, Daniel J. Lovell, Nicolino Ruperto, the Paediatric Rheumatology International Trials Organisation (PRINTO); the Pediatric Rheumatology Collaborative Study Group (PRCSG), Hermine I. Brunner, Lyudmila Grebenkina, Irina Nikishina, Ekaterina Alexeeva, Vyacheslav Chasnyk, Carlos Abud‐Mendoza, Nadina Rubio‐Pérez, Heinrike Schmeling, María del Rocio Maldonado‐Velázquez, Diane Brown, Andrew Zeft, Esi Morgan, C. Egla Rabinovich, Daniel Kingsbury, Hulya Bukulmez, Beth Gottlieb, Thomas Griffin, Lisa Imundo, Stacey Tarvin, Earl Silverman, Alberto Martini, Daniel L. Lovell, Nicolino Ruperto   +52 more
wiley   +1 more source

Facts 1999-2000 North Carolina Central University [PDF]

, 1999
Facts 1999-2000 North Carolina Central ...
Office of Institutional Research and Analysis , North Carolina Central University, NC DOCKS at North Carolina Central University   +1 more
core  

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Arthritis &Rheumatology, EarlyView.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week, double‐blind, placebo‐controlled, phase 3 Program for Evaluation
Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar   +20 more
wiley   +1 more source